Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats

Journal of Bone and Mineral Research

Volumn 16, Issue 4, 2001, Pages 765-773

  Hua Zhu Ke, ^a   Qi, H ^a   Chidsey Frink, K L ^a   Crawford, D T ^a   Thompson, D D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Body composition; Lasofoxifene; Male osteoporosis; Selective estrogen receptor modulators; Total serum cholesterol

Indexed keywords

LASOFOXIFENE; OSTEOCALCIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGED; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE ATROPHY; BONE MASS; BONE STRENGTH; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; MALE; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; PROSTATE EPITHELIUM; RAT;

EID: 0035082747     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2001.16.4.765     Document Type: Article

References (40)

1. Epidemiology of fractures
2. Hip fractures in the elderly: A world-wide projection
3. Risk factors for low bone mass in men
4. Androgens and bone: Clinical aspects
5. Sex steroids and bone mass in older men
6. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo study
7. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen
8. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men
9. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
10. Preliminary evidence for impaired estrogen receptor-α protein expression in osteoblast and osteocytes from men with idiopathic osteoporosis
11. A pharmacological review of raloxifene
12. Raloxifene (LY 139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
13. Raloxifene preserves bone strength and bone mass in ovariectomized rats
14. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats
15. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model
16. Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women
17. Selective estrogen receptor modulators: Clinical spectrum
18. The effects of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
19. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
20. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models
21. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat
22. Tetracycline-based histologic analysis of bone remodeling
23. Comparision of three-point bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia
24. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ-/- mice
25. Processing of undecalcified bone specimens for bone histomorphometry
26. Bone histomorphometry: Standardization of nomenclature, symbols, and units
27. Histomorphometric assay of the growing long bone
28. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents, human PTH (1-38), and combination therapy, assessed in aged ovariectomized rats
29. Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia
30. Basic biomechanical measurements of bone: A tutorial
31. Multisample inference
32. Hip and vertebral fractures
33. Oral estrogen improves serum lipid, homocysteine and fibrinolysis in elderly men
34. Action of androgen versus estrogen in male skeletal homeostasis
35. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
36. Increased bone mass as a results of estrogen therapy in a man with aromatase deficiency
37. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice
38. Relations between histologic indices of bone formation: Implication for the pathogenesis of spinal osteoporosis
39. Evidence for a diminished maturation of preosteoblasts into osteoblasts during aging in rats: An ultrastructural analysis
40. Age-dependent morphometric alterations in the distal femora of male and female rats